Literature DB >> 6361595

Plasma catecholamines and autonomic nervous system function in patients with early renal insufficiency and hypertension: effect of clonidine.

D Levitan, S G Massry, M Romoff, V M Campese.   

Abstract

Plasma catecholamines, hand-grip exercise and orthostatic stress were used to assess sympathetic nerve function in 14 hypertensive patients with mild to moderate renal failure and, for comparison, in 14 age-matched normal subjects. Furthermore, acute and chronic administrations of clonidine were used to determine a participation of the sympathetic nervous system in the maintenance of hypertension in these patients. Baseline mean blood pressure (MBP), plasma norepinephrine (NE), plasma renin activity (PRA) and aldosterone were elevated in patients with renal failure. During hand-grip exercise, the rise in MBP and in heart rate was blunted in these patients. During orthostasis, MBP decreased more while the increments in NE were greater in hypertensive patients that in normal subjects. Acute administration of clonidine (200 micrograms orally) resulted in a significant decrease in MBP, heart rate, NE, PRA, and aldosterone. There was a significant (p less than 0.01) correlation between the decrease in NE and the fall in MBP. After 6 weeks of treatment, clonidine produced a significant decrease in MBP, heart rate, NE and aldosterone, but not in PRA. Chronic treatment with clonidine produced a slight but significant (p less than 0.05) rise in serum potassium and in serum creatinine. Exchangeable sodium and plasma volume did not change significantly. The data indicate that abnormalities in the function of the sympathetic nervous system are already evident in patients with mild to moderate renal failure. The data also suggest that the sympathetic nervous system may participate in the maintenance of the hypertension in these patients.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6361595     DOI: 10.1159/000183111

Source DB:  PubMed          Journal:  Nephron        ISSN: 1660-8151            Impact factor:   2.847


  8 in total

Review 1.  Cardiovascular Autonomic Dysfunction in Chronic Kidney Disease: a Comprehensive Review.

Authors:  Ibrahim M Salman
Journal:  Curr Hypertens Rep       Date:  2015-08       Impact factor: 5.369

2.  Intravenous alprazolam challenge in normal subjects. Biochemical, cardiovascular, and behavioral effects.

Authors:  E D Risby; J K Hsiao; R N Golden; W Z Potter
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

Review 3.  Renal denervation--implications for chronic kidney disease.

Authors:  Roland Veelken; Roland E Schmieder
Journal:  Nat Rev Nephrol       Date:  2014-04-15       Impact factor: 28.314

Review 4.  Renal sympathetic nervous system and the effects of denervation on renal arteries.

Authors:  Arun Kannan; Raul Ivan Medina; Nagapradeep Nagajothi; Saravanan Balamuthusamy
Journal:  World J Cardiol       Date:  2014-08-26

Review 5.  Autonomic cardiovascular alterations as therapeutic targets in chronic kidney disease.

Authors:  Gino Seravalle; Fosca Quarti-Trevano; Jennifer Vanoli; Chiara Lovati; Guido Grassi
Journal:  Clin Auton Res       Date:  2021-02-19       Impact factor: 4.435

6.  Endovascular renal denervation: a novel sympatholytic with relevance to chronic kidney disease.

Authors:  Neil A Hoye; James C Baldi; Tracey L Putt; John B Schollum; Gerard T Wilkins; Robert J Walker
Journal:  Clin Kidney J       Date:  2013-11-08

Review 7.  Autonomic Cardiovascular Alterations in Chronic Kidney Disease: Effects of Dialysis, Kidney Transplantation, and Renal Denervation.

Authors:  Fosca Quarti-Trevano; Gino Seravalle; Raffaella Dell'Oro; Giuseppe Mancia; Guido Grassi
Journal:  Curr Hypertens Rep       Date:  2021-02-13       Impact factor: 5.369

8.  Upregulation of the Renin-Angiotensin-aldosterone-ouabain system in the brain is the core mechanism in the genesis of all types of hypertension.

Authors:  Hakuo Takahashi
Journal:  Int J Hypertens       Date:  2012-12-17       Impact factor: 2.420

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.